Resources

Publish Date
Letters
C4IP Letter to House Judiciary Subcommittee on Courts, Intellectual Property, Artificial Intelligence, and the Internet RE: U.S. Patent and Trademark Office
Letters
C4IP Letter to Senate Judiciary Committee RE: Hearing on China and IP Theft
Public Comments
C4IP Comments RE: The 2026 Special 301 Review (USTR-2025-0243)
Public Comments
C4IP Response RE: OSTP RFI on Accelerating American Scientific Enterprise
Letters
C4IP Letter to Senate Judiciary Subcommittee on Intellectual Property RE: the American Music Fairness Act of 2025
Letters
C4IP Letter to USTR RE: US-EU Trade Agreement
Public Comments
C4IP Comments RE: Revision to Rules of Practice Before PTAB (PTO-P-2025-0025)
Infographics & Fact Sheets
PREVAIL in Comparison to the Current and Previous Administration’s Procedures for PTAB
Public Comments
C4IP Comments RE: India’s Invitation to Comment on Its Drug Approval Regime
Public Comments
C4IP Comments RE: Operation of the Agreement between the United States of America, the United Mexican States, and Canada (USTR-2025-0004)
Letters
C4IP Letter to Senate and House IP Subcommittees RE: Designating October as National IP Month
Letters
C4IP Letter to Senate Judiciary Subcommittee on Intellectual Property RE: PERA Hearing
Resources:

Resources:

C4IP Comments RE: PAHPA,

07/10/2023

Resources:

Resources:

Reaffirm and Refine: A Government Agenda for Intellectual Property,

07/05/2023

Resources:

Resources:

Comparison of the PREVAIL Act and the USPTO’s ANPRM on PTAB,

06/26/2023

Resources:

Resources:

C4IP Comments RE: Discretionary Institution Practices, Petition Word-Count Limits, and Settlement Practices for America Invents Act Trial Proceedings before the Patent Trial and Appeal Board (PTO–P–2020–0022),

06/20/2023

Resources:

Resources:

C4IP Public Interest Comments RE: ITC Inv. No. 337-TA-1276 – Certain Light-Based Physiological Measurement Devices and Components Thereof,

06/05/2023

Resources:

Resources:

C4IP Letter to House Ways & Means Subcommittee on Health RE: Hearing on Medical Innovation and Patient Access,

05/10/2023

Resources:

Resources:

C4IP Written Submission for Inv. No. 332-596,

04/26/2023

Resources:

Resources:

Public Comments on European Commission Draft SEP Regulation,

04/19/2023

Resources:

Resources:

C4IP Response to CMS Solicitation of Comments Concerning Initial Guidance on the Inflation Reduction Act’s (IRA) Medicare Drug Negotiation Program,

04/14/2023

Resources:

Resources:

C4IP Post-Hearing Brief RE: U.S. International Trade Commission Investigation No. 332-596: COVID-19 Diagnostics and Therapeutics: Supply, Demand, and TRIPS Agreement Flexibilities,

03/29/2023

Resources:

Resources:

C4IP Testimony RE: U.S. International Trade Commission Investigation No. 332-596: COVID-19 Diagnostics and Therapeutics: Supply, Demand, and TRIPS Agreement Flexibilities,

03/29/2023

Resources:

Resources:

C4IP Letter to Senate HELP Committee RE: The Bayh-Dole Act and 28 U.S. Code § 1498,

03/17/2023

Scroll to Top